TP53 and colorectal carcinoma: Anticancer drug discovery and development are one of the great advancements, and in this manuscript, we demonstrate that ITH-6 is a potent cytotoxic agent against p53 mutant CRC cells and has a preferable cytotoxic profile compared with other drugs that are already approved for CRC.